IL154169A0 - Packaging of positive-strand rna virus replicon particles - Google Patents

Packaging of positive-strand rna virus replicon particles

Info

Publication number
IL154169A0
IL154169A0 IL15416901A IL15416901A IL154169A0 IL 154169 A0 IL154169 A0 IL 154169A0 IL 15416901 A IL15416901 A IL 15416901A IL 15416901 A IL15416901 A IL 15416901A IL 154169 A0 IL154169 A0 IL 154169A0
Authority
IL
Israel
Prior art keywords
replicon particles
positive
packaging
rna virus
strand rna
Prior art date
Application number
IL15416901A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of IL154169A0 publication Critical patent/IL154169A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36151—Methods of production or purification of viral material
    • C12N2770/36152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
IL15416901A 2000-08-29 2001-08-28 Packaging of positive-strand rna virus replicon particles IL154169A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22890600P 2000-08-29 2000-08-29
PCT/US2001/041888 WO2002018585A2 (en) 2000-08-29 2001-08-28 Packaging of positive-strand rna virus replicon particles

Publications (1)

Publication Number Publication Date
IL154169A0 true IL154169A0 (en) 2003-07-31

Family

ID=22859031

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15416901A IL154169A0 (en) 2000-08-29 2001-08-28 Packaging of positive-strand rna virus replicon particles

Country Status (13)

Country Link
US (2) US7034141B2 (de)
EP (1) EP1326990B1 (de)
JP (1) JP2004507249A (de)
KR (1) KR20030074594A (de)
CN (1) CN1250731C (de)
AT (1) ATE373721T1 (de)
AU (2) AU9322201A (de)
BR (1) BR0113577A (de)
CA (1) CA2424052A1 (de)
DE (1) DE60130569D1 (de)
IL (1) IL154169A0 (de)
MX (1) MXPA03001680A (de)
WO (1) WO2002018585A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
MXPA03001680A (es) * 2000-08-29 2004-11-01 Wyeth Corp Empaque de particulas de un replicon del virus de acido ribonucleico (arn) de hebra positiva.
WO2002072803A2 (en) 2001-03-09 2002-09-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Subgenomic replicons of the flavivirus dengue
ES2330202T5 (es) * 2001-09-06 2014-01-20 Alphavax, Inc. Sistemas vectores basados en replicones de alfavirus
ATE315660T1 (de) * 2002-05-16 2006-02-15 Bavarian Nordic As Intergene regionen als insertionsstellen im genom von modifiziertem vaccinia virus ankara (mva)
US20040053225A1 (en) * 2002-09-13 2004-03-18 Large Scale Biology Corporation Enhancement of virus induced gene silencing (VIGS) through viral-based expression of inverted-repeats
CA2501168A1 (en) * 2002-11-25 2004-06-10 Bavarian Nordic A/S Recombinant poxvirus comprising at least two cowpox ati promoters
US7442381B2 (en) * 2003-03-20 2008-10-28 Alphavax, Inc. Alphavirus replicons and helper constructs
EP2363143A3 (de) * 2003-03-28 2012-02-15 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services MVA-exprimierende modifizierte HIV-Hüll-, GAG- und POL-Gene
ES2222095B1 (es) * 2003-07-02 2005-11-16 Instituto Nacional De Investigacion Y Tecnologia Agraria Y Alimentaria Inia Virus adn recombinantes que comprenden un adn complementario de un replicon de un virus arn y sus aplicaciones.
DE602004021260D1 (de) * 2003-07-11 2009-07-09 Alphavax Inc Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren
WO2005028634A2 (en) * 2003-09-18 2005-03-31 Emory University Improved mva vaccines
US7998733B2 (en) * 2004-10-05 2011-08-16 Merial Limited Chimeric vectors
FR2887259B1 (fr) * 2005-06-21 2007-09-14 Agronomique Inst Nat Rech CONSTRUCTION D'ADNc D'ALPHAVIRUS DE SALMONIDES
EP1835031A1 (de) * 2006-03-14 2007-09-19 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Verwendung eines rekombinanten modifizierten Vaccinia Ankara Virus (MVA) zur Behandlung der Typ-I Hypersensitivität in einem lebenden Tier einschließlich des Menschen
EP1925318A1 (de) * 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Rekombinanter modifizierter Vaccinia Virus Ankara (MVA)-basierter Impfstoff gegen Vogelgrippe
US8460913B2 (en) 2007-06-21 2013-06-11 Alpha Vax, Inc. Promoterless cassettes for expression of alpha virus structural proteins
CN101226196B (zh) * 2008-02-02 2012-05-09 南方医科大学 一种检测ⅱ型登革病毒ns1抗原的免疫诊断试剂盒
US9052321B2 (en) * 2008-10-03 2015-06-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Flavivirus-based system for production of hepatitis C virus (HCV)
CN101551393B (zh) * 2009-04-02 2012-09-19 南方医科大学 一种检测ⅳ型登革病毒ns1抗原的免疫诊断试剂盒
CN104513820B (zh) * 2013-09-30 2017-08-04 中国人民解放军军事医学科学院微生物流行病研究所 DNA片段及其在制备H5N1亚型流感Guassia荧光素酶报告病毒中的应用
EP3105311A1 (de) 2014-02-10 2016-12-21 Univercells NV System, vorrichtung und verfahren zur herstellung von biomolekülen
WO2016204983A1 (en) * 2015-06-19 2016-12-22 Seracare Life Sciences, Inc. Sindbis control virus
ES2921605T3 (es) 2016-01-29 2022-08-30 Bavarian Nordic As Vacuna contra el virus de la encefalitis equina basada en el virus de la variolovacuna modificado Ankara (VMA) recombinante
WO2017162265A1 (en) * 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Trans-replicating rna
WO2018023473A1 (zh) * 2016-08-03 2018-02-08 台湾生物制剂股份有限公司 以整体表现细胞作为抗原载体及其于制备疫苗或诊断试剂及筛选单株抗体的应用
US11167027B2 (en) 2017-11-06 2021-11-09 Intervet Inc. Multivalent feline vaccine
WO2019115090A1 (en) * 2017-12-15 2019-06-20 Intervet International B.V. Multivalent feline vaccine
CN109806390A (zh) * 2019-01-07 2019-05-28 康希诺生物股份公司 一种SamRNA疫苗及其制备方法
CN109943590B (zh) * 2019-04-18 2022-11-18 西南大学 一种复制缺陷型猪圆环病毒、其制备方法及应用
EP3782465B1 (de) 2019-08-23 2023-08-30 Universität Potsdam Transgenes zebrafischmodell für schlaganfall
CN112852841A (zh) * 2021-02-03 2021-05-28 郑州大学 一种高效表达目的蛋白的顺式复制子rna构建体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792462A (en) * 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
MXPA03001680A (es) * 2000-08-29 2004-11-01 Wyeth Corp Empaque de particulas de un replicon del virus de acido ribonucleico (arn) de hebra positiva.

Also Published As

Publication number Publication date
US7034141B2 (en) 2006-04-25
WO2002018585A2 (en) 2002-03-07
WO2002018585A8 (en) 2003-04-24
ATE373721T1 (de) 2007-10-15
BR0113577A (pt) 2004-07-06
JP2004507249A (ja) 2004-03-11
US20040029279A1 (en) 2004-02-12
CA2424052A1 (en) 2002-03-07
KR20030074594A (ko) 2003-09-19
CN1250731C (zh) 2006-04-12
DE60130569D1 (de) 2007-10-31
EP1326990B1 (de) 2007-09-19
US20060141602A1 (en) 2006-06-29
AU2001293222B2 (en) 2007-09-20
MXPA03001680A (es) 2004-11-01
AU9322201A (en) 2002-03-13
CN1471583A (zh) 2004-01-28
EP1326990A2 (de) 2003-07-16
WO2002018585A3 (en) 2003-01-23

Similar Documents

Publication Publication Date Title
AU9322201A (en) Packaging of positive-strand rna virus replicon particles
PL398576A1 (pl) Preparaty szczepionek, preparaty farmaceutyczne, atenuowany wirus grypy, sposoby szczepienia, sposoby zapobiegania chorobie zakaznej, sposoby leczenia lub profilaktyki nowotworów, kompozycje szczepionek i kompozycje farmaceutyczne
EP1594536A4 (de) Adjuvante influenza-vakzine
ATE556704T1 (de) Pulverinhalator-formulierungen
IL145702A0 (en) Recombination influenza viruses for vaccines and gene theraphy
MY129263A (en) Vaccine composition
MY145753A (en) Novel cyclosporin analog formulations
IL130075A0 (en) A vaccine for eliciting an immune response to an antigen in an animal
IL147447A0 (en) Production of attenuated, human-bovine chimeric respiratory syncytial virus vaccines
WO2002087494A3 (en) Novel vaccine
WO2006083286A3 (en) Genetically engineered swine influenza virus and uses thereof
WO2006088481A3 (en) Genetically engineered equine influenza virus and uses thereof
EP2502998A3 (de) Rekombinanter Toxin A-/Toxin B-Impfstoff gegen Clostridium difficile
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
WO2002024897A3 (en) Conditionally replicating viral vectors and their use
WO2002078631A3 (en) Improved conditionally replicating vectors for inhibiting viral infections
WO2007046839A3 (en) New live virus vaccines
WO2000052045A3 (en) Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof
TW200509964A (en) VP1 of foot-and-mouth disease virus
WO2004058807A3 (en) Mhc class i restricted t-cell stimulating peptides from hepatitis b virus
WO2004041842A3 (en) Epitopes of hepatitis c virus
WO2004092207A3 (en) Respiratory syncytial virus (rsv) peptides
WO2004039945A3 (en) Preventive and therapeutic aids vaccines
MXPA04000431A (es) Formulacion vacunal potenciada por la combinacion de un adn con un antigeno.
WO2001078650A3 (en) Vaccines for protection against borrelia burgdorferi